natgillin/translations-raw huggingface dataset:
In the prevention of cardiovascular problems, Kinzalmono had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Pri preprečevanju srčno-žilnih težav je bilo zdravilo Kinzalmono enako učinkovito kot ramipril, pri čemer je okoli 17 % bolnikov umrlo, bilo hospitaliziranih zaradi srčno-žilnih težav oziroma je doživelo srčni napad ali možgansko kap.
What is Kinzalmono used for?
Za kaj se zdravilo Kinzalmono uporablja?
How does Kinzalmono work?
Kako zdravilo Kinzalmono deluje?
How is Kinzalmono used?
Kako se zdravilo Kinzalmono uporablja?
What is Kinzalmono?
Kaj je zdravilo Kinzalmono?
How has Kinzalmono been studied?
Kako je bilo zdravilo Kinzalmono raziskano?
The marketing authorisation was renewed on 17 August 2003 and on 17 August 2008.
Dovoljenje za promet z zdravilom je bilo obnovljeno 17. avgusta 2003 in 17. avgusta 2008.
NovoNorm is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Zdravilo NovoNorm ni priporočljivo za bolnike, mlajše od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti zdravila v tej starostni skupini.
It is available as round tablets (white: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Na voljo je v obliki okroglih tablet (bele: 0,5 mg; rumene: 1 mg; barve breskve: 2 mg).
NovoNorm is taken before meals, normally up to 15 minutes before each main meal.
Zdravilo NovoNorm se jemlje pred obroki, običajno do 15 minut pred vsakim glavnim obrokom.
The European Commission granted a marketing authorisation valid throughout the European Union for NovoNorm to Novo Nordisk A/S on 17 August 1998.
Evropska komisija je dovoljenje za promet z zdravilom NovoNorm, veljavno po vsej Evropski uniji, odobrila družbi Novo Nordisk A/S dne 17. avgusta 1998.
Other information about NovoNorm:
Druge informacije o zdravilu NovoNorm:
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOVONORM EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NOVONORM Povzetek EPAR za javnost
Another study looked at the effect of adding NovoNorm to metformin.
Druga študija je preučevala učinek dodajanja zdravila NovoNorm k metforminu.
The Committee recommended that NovoNorm be given marketing authorisation.
Odbor je priporočil, da se za zdravilo NovoNorm odobri dovoljenje za promet.
NovoNorm is a medicine that contains the active substance repaglinide.
NovoNorm je zdravilo, ki vsebuje zdravilno učinkovino repaglinid.
What benefit has NovoNorm shown during the studies?
Kakšne koristi je zdravilo NovoNorm izkazalo med študijami?
NovoNorm has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Zdravilo NovoNorm so preučevali v 45 kliničnih farmakoloških študijah (v katerih so preučevali, kako zdravilo deluje v telesu) in 16 kliničnih preskušanjih (v katerih so preučevali njegove učinke pri zdravljenju bolnikov s sladkorno boleznijo tipa 2).
NovoNorm should not be used in people who may be hypersensitive (allergic) to repaglinide or any of the other ingredients.
Zdravila NovoNorm ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) repaglinid ali katero koli drugo sestavino zdravila.
In the study where NovoNorm was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
V študijah, v katerih so zdravilo NovoNorm dodali metforminu, so bili učinki dveh zdravil najmanjši (enaki učinkom dveh zdravil, dodanih skupaj).
NovoNorm doses may also need to be adjusted when given with some medicines used in heart conditions, and to treat pain, asthma and other conditions.
Odmerke zdravila NovoNorm bo morda treba tudi prilagoditi, če se uporabljajo z zdravili za zdravljenje bolezni srca, bolečin, astme in drugih bolezni.
The main studies compared NovoNorm with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
V glavnih študijah so zdravilo NovoNorm primerjali z drugimi zdravili, uporabljenimi za zdravljenje sladkorne bolezni tipa 2 (glibenklamid, glipizid ali gliklazid).
A total of 2,156 patients received NovoNorm in all trials combined.
V vseh preskušanjih skupaj je zdravilo NovoNorm prejelo 2156 bolnikov.
For the full list of all side effects reported with NovoNorm, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila NovoNorm, glejte navodilo za uporabo.
What is the risk associated with NovoNorm?
Kakšna tveganja so povezana z zdravilom NovoNorm?
The Committee for Medicinal Products for Human Use (CHMP) decided that NovoNorm's benefits are greater than its risks for the treatment of type 2 diabetes.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila NovoNorm za zdravljenje sladkorne bolezni tipa 2 večje od z njim povezanih tveganj.
The most common side effects with NovoNorm (seen in between 1 and 10 patients in 100) are hypoglycaemia (low blood glucose levels), abdominal (tummy) pain and diarrhoea.
Najpogostejši neželeni učinki zdravila NovoNorm (opaženi pri 1 do 10 bolnikih izmed 100) so hipoglikemija (nizka koncentracija glukoze v krvi), bolečine v trebuhu in driska.
In all studies, NovoNorm led to a decrease in the level of HbA1c, which showed that blood glucose levels had been controlled to a similar level to that seen with the comparator medicines.
V vseh študijah je zdravilo NovoNorm povzročilo znižanje vrednosti HbA1c, kar kaže, da so bile koncentracije glukoze v krvi uravnane v podobnem obsegu kot pri primerjalnih zdravilih.
NovoNorm is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Zdravilo NovoNorm se uporablja pri bolnikih s sladkorno boleznijo tipa 2 (sladkorno boleznijo, ki ni odvisna od insulina).
The full EPAR for NovoNorm is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo NovoNorm je na voljo tukaj.
Why has NovoNorm been approved?
Zakaj je bilo zdravilo NovoNorm odobreno?
NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Zdravilo NovoNorm se lahko uporabi tudi pri bolnikih s sladkorno boleznijo tipa 2, pri katerih so koncentracije glukoze v krvi običajno dobro uravnane z dieto, vendar občasno doživijo izgubo nadzora nad glukozo v krvi.
NovoNorm may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Zdravilo NovoNorm se lahko uporablja tudi z metforminom (drugim antidiabetičnim zdravilom) pri bolnikih s sladkorno boleznijo tipa 2, pri katerih koncentracije glukoze v krvi ni mogoče zadovoljivo uravnavati samo z metforminom.
NovoNorm helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Zdravilo NovoNorm pomaga trebušni slinavki, da tvori več insulina ob obrokih in se uporablja za uravnavanje sladkorne bolezni tipa 2.
The full list of these medicines is available in the Package Leaflet.
Za celoten seznam teh zdravil glejte navodilo za uporabo.
NovoNorm produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients, leading to a blood glucose-lowering effect throughout the meal.
Pri bolnikih s sladkorno boleznijo tipa 2 se je v 30 minutah po odmerku zdravila NovoNorm pojavil dober odziv insulina na obrok, kar je povzročilo znižanje glukoze v krvi v celotnem obdobju obroka.
How has NovoNorm been studied?
Kako je bilo zdravilo NovoNorm raziskano?
What is NovoNorm used for?
Za kaj se uporablja zdravilo NovoNorm?
How does NovoNorm work?
Kako zdravilo NovoNorm deluje?
How is NovoNorm used?
Kako se zdravilo NovoNorm uporablja?
What is NovoNorm?
Kaj je zdravilo NovoNorm?
Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
TAMIK, capsule soft capsule
TAMIK, capsule mehka kapsula
LEK farmacevtska družba d.d., Verovskova 57, SI-1526 Ljubljana, Slovenia
LEK farmacevtska družba d.d., Verovškova 57, SI-1526 Ljubljana, Slovenia
SEGLOR LYOC 5 mg, lyophilisat oral oral lyophilisate
SEGLOR LYOC 5 mg, lyophilisat oral peroralni liofilizat
SEGLOR 5 mg, gélule 5 mg hard capsule
SEGLOR 5 mg, gélule 5 mg trda kapsula
Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution oral use ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml peroralne kapljice, raztopina ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
DET MS Tropflösung 2 mg/ 1 ml
DET MS Tropflösung 2 mg/ 1 ml raztopina
IKARAN L.P. 5 mg, comprimé à libération prolongée prolonged-release tablet
5 mg, comprimé à libération prolongée tableta s podaljšanim sproščanjem
0.2 g/ 100 ml 1 g/ 100 ml
0.2 g/ 100 ml 1 g/ 100 ml raztopina
Prolonged-released capsule, hard
kapsula s prirejenim sproščanjem, trda
2 mg/ 1 ml 10 mg/ 1 ml
2 mg/ 1 ml 10 mg/ 1 ml raztopina
0.20 g /100 ml oral drops, solution oral use
0.20 g /100 ml peroralna raztopina peroralna uporaba
Dihydroergotaminum Filofarm2 mg/g oral solution
Dihydroergotaminum Filofarm2 mg/g peroralna raztopina peroralna uporaba
2 mg/ 1 ml solution
2 mg/ 1 ml raztopina
Ergotam-CT 5,0mg Retardkapseln
Ergotam-CT 5,0mg Retardkapseln kapsula s podaljšanim sproščanjem
2 mg/ml oral drops, solution oral use
2 mg/ml peroralna raztopina peroralna uporaba
Ergotam-CT 2,5mg Retardkapseln
Ergotam-CT 2,5mg Retardkapseln kapsula s podaljšanim sproščanjem
Tablets
Farmacevtska oblika
1 bottle
1 steklenička
Strength
Vsebina
3750 U
3750 e.
Further information on Cimzia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/cimzia.
Nadaljnje informacije za zdravilo Cimzia so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/cimzia.
What measures are being taken to ensure the safe and effective use of Cimzia?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cimzia?
The European Medicines Agency decided that Cimzia's benefits are greater than its risks and that it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Cimzia večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
These packs will include information on the safety of the medicine.
Gradivo bo vsebovalo informacije o varnosti zdravila.
Cimzia received a marketing authorisation valid throughout the EU on 1 October 2009.
Za zdravilo Cimzia je bilo 1. oktobra 2009 izdano dovoljenje za promet, veljavno po vsej EU.
The most common side effects with Cimzia (affecting up to 1 in 10 people) are bacterial infections including abscesses (a swollen area where pus has collected), viral infections (including herpes, papillomavirus and influenza), eosinophilic disorders (disorders of eosinophils, a type of white blood cell), leucopenia (low white blood cell counts), nausea (feeling sick), headaches (including migraine), sensory abnormalities (such as numbness, tingling and burning sensation), high blood pressure, hepatitis (liver inflammation) including increased levels of liver enzymes, rash, fever, pain, weakness, itching and reactions at the injection site.
Najpogostejši neželeni učinki zdravila Cimzia (ki se lahko pojavijo pri največ 1 do 10 bolnikov) so bakterijske okužbe, vključno z abscesi (oteklimi gnojnimi tvorbami), virusne okužbe (vključno s herpesom, papiloma virusom in gripo), eozinofilna obolenja (obolenja eozinofilcev, tj. vrste belih krvničk), levkopenija (nizko število belih krvničk), navzeja (siljenje na bruhanje), glavoboli (vključno z migreno), neobičajne zaznave (kot je npr. odrevenelost, mravljinčenje, žgoč občutek), visok krvni tlak, hepatitis (vnetje jeter), vključno s povišanimi ravnmi jetrnih encimov, izpuščaji, povišana telesna temperatura, bolečine, šibkost, srbenje in reakcije na mestu injiciranja.
Other information about Cimzia
Druge informacije o zdravilu Cimzia
Cimzia is a medicine that is used in adults to treat the following diseases:
Zdravilo Cimzia se uporablja pri odraslih za zdravljenje naslednjih bolezni:
Pegylation decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Pegilacija zmanjšuje hitrost izločanja snovi iz telesa in omogoča manj pogosto dajanje zdravila.
The main measure of effectiveness was the number of patients who responded to treatment after 16 weeks, meaning that symptom scores improved by 75% or more.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 16 tednih odzvali na zdravljenje, kar pomeni, da so se ocene njihovih simptomov izboljšale za najmanj 75 %.
Patients will be given a reminder card with safety information that they should carry with them.
Bolniki bodo prejeli posebno opozorilno kartico z informacijami o varnosti zdravila, ki jo morajo imeti vedno pri sebi.
A monoclonal antibody is a protein that has been designed to recognise and attach to a specific structure in the body.
Monoklonsko protitelo je vrsta beljakovine, ki je bila zasnovana tako, da v telesu prepozna določeno strukturo in se veže nanjo.
Nine main studies involving over 3,000 patients have found Cimzia effective for reducing symptoms of inflammatory conditions.
V devetih glavnih študijah, v katere je bilo vključenih več kot 3 000 bolnikov, so ugotovili, da zdravilo Cimzia učinkovito zmanjšuje simptome vnetnih bolezni.
Side effects reported with Cimzia are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Cimzia, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cimzia have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cimzia upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Cimzia have been shown in studies?
Kakšne koristi zdravila Cimzia so se pokazale v študijah?
As for all medicines, data on the use of Cimzia are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Cimzia stalno spremljajo.
An overview of Cimzia and why it is authorised in the EU
Pregled zdravila Cimzia in zakaj je odobreno v EU
A third study compared Cimzia with placebo as well as another medicine called etanercept.
V tretji študiji so zdravilo Cimzia primerjali s placebom in drugim zdravilom, imenovanim etanercept.
Why is Cimzia authorised in the EU?
Zakaj je bilo zdravilo Cimzia odobreno v EU?
Cimzia is mostly used for conditions that are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Zdravilo Cimzia se večinoma uporablja, kadar je bolezen huda ali zmerna ali pa se poslabšuje oziroma kadar bolnik ne more uporabljati drugega zdravljenja.
What is Cimzia and what is it used for?
Kaj je zdravilo Cimzia in za kaj se uporablja?
Cimzia must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (inability of the heart to pump enough blood around the body).
Zdravilo Cimzia se ne sme uporabljati pri bolnikih z aktivno tuberkulozo, drugimi hudimi okužbami ali zmernim do hudim srčnim popuščanjem (stanjem, pri katerem srce ne zmore črpati dovolj krvi po telesu).
It is made up of a monoclonal antibody, certolizumab, which has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Sestavljena je iz monoklonskega protitelesa (certolizumaba), ki je bilo „pegilirano“ (pripojeno na kemično snov, imenovano polietilen glikol).
The studies included adults with active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and moderate to severe plaque psoriasis:
V študije so bili vključeni odrasli z aktivnim revmatoidnim artritisom, aksialnim spondiloartritisom, psoriatičnim artritisom in zmerno do hudo psoriazo v plakih.
For more information about using Cimzia, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Cimzia glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Cimzia?
Kakšna tveganja so povezana z zdravilom Cimzia?
The company that markets Cimzia will provide educational packs for doctors who will prescribe Cimzia.
Družba, ki trži zdravilo Cimzia, bo zagotovila izobraževalno gradivo za zdravnike, ki bodo predpisovali to zdravilo.
By blocking TNF-alpha, certolizumab pegol reduces inflammation and other symptoms of the diseases.
Certolizumab pegol z zaviranjem TNF-alfa zmanjša vnetje in druge simptome teh bolezni.
After this, depending on the condition being treated, patients should continue with 200 mg or 400 mg, given as one or two injections every 2 or 4 weeks.
Nato se odvisno od zdravljene bolezni zdravljenje nadaljuje tako, da bolniki prejmejo 200- ali 400-miligramski odmerek, ki se vbrizga z eno ali dvema injekcijama vsaka dva ali štiri tedne.
Cimzia can only be obtained with a prescription and treatment should only be started by a specialist doctor who has experience in diagnosing and treating the diseases that Cimzia is used to treat.
Predpisovanje in izdaja zdravila Cimzia je le na recept, zdravljenje z njim pa lahko uvede le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se to zdravilo uporablja.
• In the treatment of moderate to severe plaque psoriasis, Cimzia was compared with placebo in two main studies.
• V zvezi z zdravljenjem zmerne do hude psoriaze v plakih so zdravilo Cimzia primerjali s placebom v dveh glavnih študijah.
The active substance in Cimzia, certolizumab pegol, reduces the activity of the immune system (the body's defences).
Učinkovina zdravila Cimzia, certolizumab pegol, zavira delovanje imunskega sistema (obrambnega mehanizma telesa).
In patients with active rheumatoid arthritis who had never received DMARDs, treatment with Cimzia led to sustained remission (no detectable disease activity) after 52 weeks of treatment.
Pri bolnikih z aktivnim revmatoidnim artritisom, ki še niso prejemali imunomodulirajočih antirevmatičnih zdravil, je zdravljenje z zdravilom Cimzia po 52 tednih zdravljenja povzročilo trajnejšo remisijo (tj. ni bilo zaznavne aktivnosti bolezni).
Certolizumab pegol has been designed to attach to a messenger protein in the body called tumour necrosis factor alpha (TNF-alpha).
Certolizumab pegol je bil zasnovan tako, da se v telesu veže na beljakovinskega prenašalca, imenovanega tumorje nekrotizirajoči faktor alfa (TNF-alfa).
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Cimzia is used for.
Ta prenašalec sodeluje pri povzročanju vnetja in je pri bolnikih z boleznimi, ki se zdravijo z zdravilom Cimzia, prisoten v visokih koncentracijah.
Also, X-rays showed that joint damage worsened to a lesser extent in patients who received Cimzia.
Poleg tega so rentgenski posnetki pokazali, da so bile poškodbe sklepov pri bolnikih, ki so prejemali zdravilo Cimzia, manjše.
After training, patients may inject Cimzia themselves if their doctor agrees.
Ob soglasju zdravnika si lahko bolniki po opravljenem usposabljanju zdravilo Cimzia vbrizgavajo sami.
It is given by injection under the skin, usually in the thigh or abdomen (belly).
Vbrizga se z injekcijo v podkožje, običajno v stegno ali trebuh.
Similar results were seen in a study with patients who had not adequately responded to other medicines such as methotrexate.
Podobne rezultate so opazili v študiji pri bolnikih, ki se niso ustrezno odzvali na druga zdravila, na primer metotreksat, vendar je bil odmerek zdravila Cimzia, uporabljen v tej študiji, večji od običajnega.
How does Cimzia work?
Kako zdravilo Cimzia deluje?
• For active rheumatoid arthritis that had not improved adequately with disease-modifying antirheumatic drug (DMARD) treatment, two main studies found Cimzia effective when used with methotrexate when compared with placebo (dummy treatment).
• V zvezi z aktivnim revmatoidnim artritisom, ki se ni ustrezno izboljšal z imunomodulirajočimi antirevmatičnimi zdravili (DMARD), je bilo v dveh glavnih študijah ugotovljeno, da je zdravilo Cimzia v primerjavi s placebom (zdravilom brez učinkovine) učinkovito, kadar se daje skupaj z metotreksatom.
• plaque psoriasis, a disease causing red, scaly patches on the skin.
• psoriaze v plakih (bolezni, ki povzroča nastajanje rdečih, luskastih zaplat na koži).
• active rheumatoid arthritis (a disease causing inflammation of the joints) when it is used in combination with another medicine, methotrexate, or given alone when treatment with
• aktivnega revmatoidnega artritisa (bolezni, ki povzroča vnetje sklepov), kadar se uporablja skupaj z drugim zdravilom, metotreksatom, ali se daje samostojno, če zdravljenje z metotreksatom ni primerno;
For detailed information on the use of Cimzia in all conditions, see the summary of product characteristics.
Za več informacij glede uporabe zdravila Cimzia pri vseh boleznih glejte povzetek glavnih značilnosti zdravila.
In the first study, symptoms were reduced by at least 20% in 57% of patients who received Cimzia (141 out of 246) compared with 9% of patients who received placebo (11 out of 127).
V prvi študiji so se simptomi za vsaj 20 % zmanjšali pri 57 % (141 od 246) bolnikov, ki so prejemali zdravilo Cimzia, in pri 9 % (11 od 127) bolnikov, ki so prejemali placebo.
Treatment starts with a 400-mg dose given as two injections, followed by a further 400-mg dose 2 and 4 weeks later.
Temu sledi dodaten 400-miligramski odmerek dva in štiri tedne pozneje.
After 12 weeks of treatment, Cimzia 200 mg every two weeks led to 61% of patients responding and 67% responding with Cimzia 400 mg every two weeks compared with 53% of patients receiving etanercept and 5% of patients receiving placebo.
Po 12 tednih zdravljenja se je odzvalo 61 % bolnikov, ki so prejemali 200-miligramski odmerek zdravila Cimzia vsaka dva tedna, 67 % bolnikov, ki so prejemali 400-miligramski odmerek zdravila Cimzia vsaka dva tedna, 53 % bolnikov, ki so prejemali etanercept, in 5 % bolnikov, ki so prejemali placebo.
In a study in 879 patients who had never received DMARDs, treatment with Cimzia and methotrexate led to remission in almost 29% of patients (189 out of 655), compared with 15% (32 out of 213) of patients receiving placebo with methotrexate.
V študiji pri 879 bolnikih, ki še niso prejemali imunomodulirajočih antirevmatičnih zdravil, je do remisije prišlo pri skoraj 29 % (189 od 655) bolnikov, ki so prejemali zdravilo Cimzia in metotreksat, in pri 15 % (32 od 213) bolnikov, ki so prejemali placebo in metotreksat.
• A study in patients with axial spondyloarthritis showed that symptoms improved by at least 20% after 12 weeks in around 60% of patients treated with Cimzia compared with around 40% of patients receiving placebo.
• Študija pri bolnikih z aksialnim spondiloartritisom je pokazala, da je po 12 tednih do vsaj 20-odstotnega izboljšanja simptomov prišlo pri približno 60 % bolnikov, ki so prejemali zdravilo Cimzia, in pri približno 40 % bolnikov, ki so prejemali placebo.
• For psoriatic arthritis, symptoms improved by at least 20% in 58% of patients treated with Cimzia 200 mg every two weeks compared with 24% of patients receiving placebo.
• Simptomi psoriatičnega artritisa so se za vsaj 20 % izboljšali pri 58 % bolnikov, zdravljenih z 200-miligramskim odmerkom zdravila Cimzia vsaka dva tedna, in pri 24 % bolnikov, ki so prejemali placebo.
For patients receiving Cimzia 400 mg every four weeks 52% saw an improvement.
Pri bolnikih, zdravljenih s 400-miligramskim odmerkom zdravila Cimzia vsake štiri tedne, so se simptomi izboljšali pri 52 %.